Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
$63.22
$63.22
$63.22
$63.22
$24.43B0.26279 shsN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$159.97
-2.3%
$144.04
$91.86
$254.15
$7.85B1.491.03 million shs263,828 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$44.99
-0.4%
$42.32
$22.13
$49.62
$12.30B0.282.51 million shs841,433 shs
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$165.21
$167.50
$93.00
$175.95
$10.70B1.31837,472 shs57 shs
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$42.98
$42.86
$22.89
$52.23
$4.46B1.581.92 million shsN/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
0.00%0.00%0.00%0.00%+3.36%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
+3.06%+4.14%+8.33%+64.36%-19.28%
Exelixis, Inc. stock logo
EXEL
Exelixis
+2.50%-1.61%+6.23%+27.92%+104.85%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.00%0.00%0.00%0.00%0.00%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.1847 of 5 stars
2.12.00.04.72.92.51.9
Exelixis, Inc. stock logo
EXEL
Exelixis
4.7092 of 5 stars
2.21.00.04.33.22.54.4
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
0.00
N/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.25
Hold$174.549.11% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.48
Hold$44.72-0.60% Downside
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.00
N/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EXEL, SYNH, PRAH, CRL, and BTGGF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$29.00 ➝ $40.00
7/9/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$170.00 ➝ $180.00
7/9/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$150.00 ➝ $200.00
7/8/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Sector Perform$45.00 ➝ $50.00
6/30/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$47.00 ➝ $53.00
6/24/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$50.00
6/24/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$29.00 ➝ $60.00
6/23/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
6/23/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$43.00 ➝ $55.00
6/23/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$47.00 ➝ $50.00
6/12/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $47.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.05B1.94$21.82 per share7.33$67.80 per share2.36
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.17B5.66$1.97 per share22.88$7.86 per share5.72
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$3.18B3.36$6.09 per share27.11$23.06 per share7.16
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$5.39B0.83$6.72 per share6.40$33.96 per share1.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/A0.00N/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$22.20M-$0.65N/A14.545.38-0.66%15.19%6.93%8/6/2025 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$521.27M$2.2020.5017.640.8827.99%28.81%21.94%8/5/2025 (Estimated)
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$197.04M$3.9050.5226.31N/A6.40%20.49%7.07%N/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$266.50M$0.6962.29N/A1.31%8.63%3.66%N/A

Latest EXEL, SYNH, PRAH, CRL, and BTGGF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.50N/AN/AN/A$983.76 millionN/A
8/5/2025Q2 2025
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.63N/AN/AN/A$574.36 millionN/A
5/7/2025Q1 2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.06$2.34+$0.28$0.50$942.34 million$984.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.78
1.43
1.16
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.50
3.44
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.74
1.21
1.21
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.77
1.20
1.20
CompanyEmployeesShares OutstandingFree FloatOptionable
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
35386.49 millionN/ANot Optionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
20,10049.12 million48.48 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,147272.71 million265.02 millionOptionable
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
18,10064.80 millionN/AOptionable
Syneos Health, Inc. stock logo
SYNH
Syneos Health
28,768103.72 million103.37 millionOptionable

Recent News About These Companies

The Escalator: Syneos Health, The FDA, Pfizer and more
Syneos Health makes senior hires
Syneos Health Gets Worker Claims Trimmed in Vaccine Bias Lawsuit
INC Research/inVentiv Health Becomes Syneos Health
Investment group will take Syneos Health private
Hayward Holdings, Inc. (HAYW)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bitcoin Group stock logo

Bitcoin Group OTCMKTS:BTGGF

$63.22 0.00 (0.00%)
As of 07/10/2025

Bitcoin Group SE, an investment holding company, engages in the cryptocurrency and blockchain businesses worldwide. The company operates a trading platform for the digital currency bitcoin under the Bitcoin.de. It also provides financial services. The company was founded in 2008 and is based in Herford, Germany. Bitcoin Group SE is a subsidiary of Priority AG.

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$160.29 -3.37 (-2.06%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$44.90 -0.28 (-0.61%)
As of 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

PRA Health Sciences stock logo

PRA Health Sciences NASDAQ:PRAH

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Syneos Health stock logo

Syneos Health NASDAQ:SYNH

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.